Hepatoma Research最新文献_第5页

Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward? 肝移植治疗肝门周围胆管癌。我们需要继续前进吗?

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2022.75

C. Dopazo, R. Charco

引用次数: 1

Current landscape and future directions for systemic treatments of hepatocellular carcinoma 肝细胞癌系统治疗的现状和未来方向

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.63

L. G. Fonseca, F. Carrilho

引用次数: 0

Challenges and barriers in hepatocellular carcinoma (HCC) surveillance for patients with non-alcoholic fatty liver disease (NAFLD) 非酒精性脂肪性肝病(NAFLD)患者肝细胞癌(HCC)监测的挑战和障碍

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2022.92

Kara Wegermann, A. Diehl, C. Moylan

引用次数: 0

Biomarkers for Living Donor Liver Transplants in Hepatocellular Carcinoma 肝细胞癌活体供肝移植的生物标志物

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.25

Edward Butt, Rupak Kulkarni, A. Moghe

引用次数: 0

Chemoembolization with Degradable Starch Microspheres (DSM-TACE): expanding indications in HCC multidisciplinary tumor board 可降解淀粉微球化疗栓塞(DSM-TACE):扩大HCC多学科肿瘤委员会的适应症

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2022.66

Umberto Rozzanigo, Francesco Gatti, Giacomo Luppi, Lorenzo Costa, Benedetto Petralia, Cecilia Pravadelli, Ivana Maioli, Michela Frisinghelli, Sergio Fersino, Riccardo Berletti, G. Pretis, Alberto Brolese

{"title":"Chemoembolization with Degradable Starch Microspheres (DSM-TACE): expanding indications in HCC multidisciplinary tumor board","authors":"Umberto Rozzanigo, Francesco Gatti, Giacomo Luppi, Lorenzo Costa, Benedetto Petralia, Cecilia Pravadelli, Ivana Maioli, Michela Frisinghelli, Sergio Fersino, Riccardo Berletti, G. Pretis, Alberto Brolese","doi":"10.20517/2394-5079.2022.66","DOIUrl":"https://doi.org/10.20517/2394-5079.2022.66","url":null,"abstract":"The role of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) management has changed over the last twenty years. There has been a trend towards an overall decline in TACE procedures, but with a more aggressive approach, repeating multiple TACE sessions in case of tumor response. The survival of treated patients was prolonged because of better patient selection and advancements in TACE techniques aimed at preserving liver function. At present, TACE is approved by the International Guidelines also outside of the BCLC intermediate stage after evaluation of a multidisciplinary tumor board (MDTB), permitting a customized treatment for every patient. An alternative therapeutic strategy is represented by hepatic chemoembolization with Degradable Starch Microspheres (DSM-TACE), which is based on the chemotherapeutic effect rather than on the ischemic damage to the liver tumor, requiring multiple cycles of treatment. The higher safety profile of DSM-TACE has broadened the indications to patients waiting for liver transplantation (with bridging or downstaging intention), at high risk of liver failure and ineligible for systemic therapies. This review summarises the scientific publications supporting the use of DSM-TACE and illustrates its indications depending on the disease stage from the Interventional Radiologist’s perspective.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67654508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategy for ERCP stenting in cholangiocarcinoma 胆管癌ERCP支架置入术的策略

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.20

Radovan Prijic, Agata Ladic, Pave Markos

{"title":"Strategy for ERCP stenting in cholangiocarcinoma","authors":"Radovan Prijic, Agata Ladic, Pave Markos","doi":"10.20517/2394-5079.2023.20","DOIUrl":"https://doi.org/10.20517/2394-5079.2023.20","url":null,"abstract":"Considering the steadily growing incidence of cholangiocarcinoma (CCA) worldwide, there is a constant need to re-evaluate and re-think its pathophysiology, diagnostic modalities, and mostly important, its treatment. No matter the histopathological appearance, endoscopic procedures - mainly Endoscopic Retrograde Cholangiopancreatography (ERCP) with stenting - are often used in the treatment of CCA complications, such as biliary obstruction when biliary drainage is indicated. Indications for preoperative biliary drainage in surgical cases are adjusted to each patient’s status. On the contrary, palliative drainage is the first option for relieving symptoms and improving the quality of life in the context of locally advanced and unresectable CCA. Further, concern about stenting techniques depends on the stricture location: Bismuth-Corlette types I and II are usually endoscopically drained with one stent placed in biliary tract, while for types III and IV, even bilateral stenting may prove inadequate. Stents used in ERCP are either plastic or self-expandable metallic stents (SEMS). Though plastic stents show some advantages over SEMS in terms of removability and possibility to adapt to a biliary tree which allows potential reinterventions, SEMS are better in terms of patency, lower complications number, and success of drainage. Besides ERCP, echo-endoscopic drainage is also an option, especially when ERCP approach has not yielded a successful drainage. The aim of this study was to show the potential of ERCP stenting in CCA treatment, its possible pitfalls, and the need to consider multiple levels of ERCP-related care.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"110 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135748992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ethnic disparities in the epidemiology, treatment, and outcome of patients with hepatocellular carcinoma in the United States. 美国肝细胞癌患者在流行病学、治疗和预后方面的种族差异。

Hepatoma Research Pub Date : 2023-01-01 Epub Date: 2023-05-18 DOI: 10.20517/2394-5079.2023.10

Mohammad Saeid Rezaee-Zavareh, Jeff Liang, Ju Dong Yang

{"title":"Ethnic disparities in the epidemiology, treatment, and outcome of patients with hepatocellular carcinoma in the United States.","authors":"Mohammad Saeid Rezaee-Zavareh, Jeff Liang, Ju Dong Yang","doi":"10.20517/2394-5079.2023.10","DOIUrl":"10.20517/2394-5079.2023.10","url":null,"abstract":"<p><p>There are significant ethnic disparities in incidence, tumor stage, curative therapy receipt, and survival among patients with hepatocellular carcinoma (HCC) in the US. While previous models had predicted an increasing trend in the incidence rate of HCC until 2030 in the US, recent studies have shown that HCC incidence plateaued in 2013 and then started to decline in 2015. The decreasing trend has been observed in all ethnicities except for American Indians/Alaska Natives, whose incidence rates of HCC continue to rise. Current evidence shows that African-Americans and Hispanics are two groups that are more likely to be diagnosed with late-stage HCC, and this finding has been consistent in different socioeconomic statuses of the patients. These two ethnic minority groups are also among those who are less likely to have curative therapy for early-stage HCC. Finally, advances in early diagnosis and treatment approaches have led to an improvement in HCC survival for all ethnicities; however, African-Americans continue to have the worst survival. More studies to find the causes of these disparities and interventions to eliminate them are urgently needed.</p>","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67654265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the interactions between lymphocytes and liver cancer stem cells in combination with immunotherapy is a promising therapeutic strategy 靶向淋巴细胞与肝癌干细胞的相互作用，结合免疫治疗是一种很有前景的治疗策略

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2022.52

Wojun Chen, Xiao-Ping Zhang, Yuan Yan, X. Sun, Lei Li

引用次数: 1

Surgical management of intrahepatic cholangiocarcinoma 肝内胆管癌的外科治疗

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.18

Ruff Samantha M.

引用次数: 0

Tumor microenvironment highlighting tumor-associated macrophages and immune cells 肿瘤微环境突出肿瘤相关的巨噬细胞和免疫细胞

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.32

Giulio Lodetti Zangrandi, Dilruba Tirpanlar, M. Pastore, C. Soldani, A. Lleo, C. Raggi

{"title":"Tumor microenvironment highlighting tumor-associated macrophages and immune cells","authors":"Giulio Lodetti Zangrandi, Dilruba Tirpanlar, M. Pastore, C. Soldani, A. Lleo, C. Raggi","doi":"10.20517/2394-5079.2023.32","DOIUrl":"https://doi.org/10.20517/2394-5079.2023.32","url":null,"abstract":"Cholangiocarcinoma (CCA) grows within a highly desmoplastic microenvironment, exhibiting a continuous interconnection with the immune infiltrate, which is characterized by an abundance of immune cells, including natural killer cells, T lymphocytes, and macrophages. The presence of inflammatory cells within the tumor microenvironment plays a crucial role in determining the aggressiveness and growth of CCA. The immune cell population engages in diverse and dynamic interactions with cancer cells. The balance of different subpopulations within CCA can generate varying responses, either inhibiting or promoting tumoral progression. The purpose of this review is to offer a comprehensive overview of the role of various immune infiltrate subpopulations within the tumor microenvironment, with a particular focus on the actions of tumor-associated macrophages (TAMs) and their critical regulation in the development and progression of CCA. TAMs play vital roles in maintaining homeostasis, facilitating tissue repair, and contributing to immune responses due to their significant functional diversity. Macrophages are present in numerous types of cancer, and their emerging role has also been observed in CCA. Recognizing and attaining a deeper comprehension of the intricate interplay between infiltrating immune cells and CCA cells is essential to identify new opportunities to advance treatment strategies.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67654448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1